Anticancer activity of β-elemene and its synthetic analogs in human malignant brain tumor cells

Anticancer Research

Volumn 33, Issue 1, 2013, Pages 65-76

  Quentin Li, Qingdi ^a,b,c   Lee, Rebecca X ^b   Liang, Huasheng ^a   Zhong, Yuhua ^a  

^a Beihai Institute of Endocrine and Metabolic Diseases   (China)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

elemene; A172; Apoptosis; Brain cancer; CCF STTG1 cells; Chinese medicine; Synthetic analogs; U 87MG

Indexed keywords

BETA ELEMENE; LIPOCORTIN 5; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TERPENOID DERIVATIVE; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SESQUITERPENES;

EID: 84873047094     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura Lima A, McCutcheon IE, Prabhu SS, Lang FF, DeMonte F and Rao G: Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg 114: 576-584, 2011.
2. Ahsan H, Neugut AI and Bruce JN: Trends in incidence of primary malignant brain tumors in USA, 1981-1990. Int J Epidemiol 24: 1078-1085, 1995.
3. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S and Davis FG: Trends in incidence of primary brain tumors in the United States, 1985-1994. Neuro Oncol 3: 141-151, 2001.
4. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards BK: Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103: 714-736, 2011.
5. Smith MA, Freidlin B, Ries LA and Simon R: Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst 90: 1269-1277, 1998.
6. Zada G, Bond AE, Wang YP, Giannotta SL and Deapen D: Incidence trends in the anatomic location of primary malignant brain tumors in the United States: 1992-2006. World Neurosurg 77: 518-524, 2012.
7. Henriksson R, Asklund T and Poulsen HS: Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: A review. J Neurooncol 104: 639-646, 2011.
8. Amelio D, Lorentini S, Schwarz M and Amichetti M: Intensitymodulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues. Radiother Oncol 97: 361-369, 2010.
9. Caldwell WL and Aristizabal SA: Treatment of glioblastoma multiforme. A review. Acta Radiol Ther Phys Biol 14: 505-512, 1975.
10. Jubelirer SJ: A review of the treatment and survival rates of 138 patients with glioblastoma multiforme. W V Med J 92: 186-190, 1996.
11. Rock K, McArdle O, Forde P, Dunne M, Fitzpatrick D, O'Neill B and Faul C: A clinical review of treatment outcomes in glioblastoma multiforme - the validation in a non-trial population of the results of a randomised Phase III clinical trial: Has a more radical approach improved survival? Br J Radiol 85: 729-733, 2012.
12. Slatkin DN: Glioblastoma treatment. Science 265: 1644-1645, 1994.
13. Dang YY, Li XC, Zhang QW, Li SP and Wang YT: Preparative isolation and purification of six volatile compounds from essential oil of Curcuma wenyujin using high-performance centrifugal partition chromatography. J Sep Sci 33: 1658-1664, 2010.
14. Guo YT: Isolation and identification of elemene from the essential oil of Curcuma wenyujin. Zhong Yao Tong Bao 8: 31-32, 1983.
15. Li QQ, Wang G, Huang F, Banda M and Reed E: Antineoplastic effect of β-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol 62: 1018-1027, 2010.
16. Li QQ, Wang G, Reed E, Huang L and Cuff CF: Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol 107: 868-876, 2010.
17. Li QQ, Wang G, Zhang M, Cuff CF, Huang L and Reed E: β-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep 22: 161-170, 2009.
18. Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, Flynn DC, Reed E and Li QQ: Antiproliferative effect of β-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci 62: 894-904, 2005.
19. Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E and Li QQ: Antitumor effect of β-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 62: 881-893, 2005.
20. Wu W, Liu K and Tang X: Preliminary study on the antitumor immuno-protective mechanism of β-elemene. Zhonghua Zhong Liu Za Zhi 21: 405-408, 1999.
21. Zhang R, Tian A, Shi X, Yu H and Chen L: Downregulation of IL-17 and IFN-γ in the optic nerve by β-elemene in experimental autoimmune encephalomyelitis. Int Immunopharmacol 10: 738-743, 2010.
22. Liu J, Zhang Z, Gao J, Xie J, Yang L and Hu S: Down-regulation effects of β-elemene on the levels of plasma endotoxin, serum TNF-α, and hepatic CD14 expression in rats with liver fibrosis. Front Med 5: 101-105, 2011.
23. Zhao J, Li QQ, Zou B, Wang G, Li X, Kim JE, Cuff CF, Huang L, Reed E and Gardner K: In vitro combination characterization of the new anticancer plant drug β-elemene with taxanes against human lung carcinoma. Int J Oncol 31: 241-252, 2007.
24. Portt L, Norman G, Clapp C, Greenwood M and Greenwood MT: Anti-apoptosis and cell survival: A review. Biochim Biophys Acta 1813: 238-259, 2011.
25. Fuchs Y and Steller H: Programmed cell death in animal development and disease. Cell 147: 742-758, 2011.
26. Han CZ and Ravichandran KS: Metabolic connections during apoptotic cell engulfment. Cell 147: 1442-1445, 2011.
27. Green DR, Galluzzi L and Kroemer G: Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 333: 1109-1112, 2011.
28. Pore MM, Hiltermann TJ and Kruyt FA: Targeting apoptosis pathways in lung cancer. Cancer Lett 305: 218-227, 2011.
29. Signore M, Ricci-Vitiani L and De Maria R: Targeting apoptosis pathways in cancer stem cells. Cancer Lett 301: 7-16, 2011.
30. Kurokawa M and Kornbluth S: Caspases and kinases in a death grip. Cell 138: 838-854, 2009.
31. Olsson M and Zhivotovsky B: Caspases and cancer. Cell Death Differ 18: 1441-1449, 2011.
32. Boatright KM and Salvesen GS: Mechanisms of caspase activation. Curr Opin Cell Biol 15: 725-731, 2003.
33. Kumar S: Mechanisms mediating caspase activation in cell death. Cell Death Differ 6: 1060-1066, 1999.
34. Fearnhead HO, Rodriguez J, Govek EE, Guo W, Kobayashi R, Hannon G and Lazebnik YA: Oncogene-dependent apoptosis is mediated by caspase-9 Proc Natl Acad Sci USA 95: 13664-13669. 1998.
35. Kaufmann T, Strasser A and Jost PJ: FAS death receptor signalling: Roles of BID and XIAP. Cell Death Differ 19: 42-50, 2012.
36. Ola MS, Nawaz M and Ahsan H: Role of BCL-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351: 41-58, 2011.
37. Martinou JC and Youle RJ: Mitochondria in apoptosis: BCL-2 family members and mitochondrial dynamics. Dev Cell 21: 92-101, 2011.
38. Zhou F, Yang Y and Xing D: BCL-2 and BCL-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J 278: 403-413, 2011.